Article
AbbVie's Rinvoq needs steep discount in eczema, cost watchdog ICER says
Rating:
0.0
Views:
97
Likes:
1
Library:
1
AbbVie is counting on rising immunology star Rinvoq to defend its top line once Humira takes a plunge off the patent cliff in 2023, but a prominent drug pricing watchdog just raised concerns over the med's cost in an important use.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value